F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented benzodiazepine derivatives acting as GABA(A) receptor subunit α2β2γ1 positive allosteric modulators and reported to be useful for the treatment of neurological disorders.
A recent F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes compounds reported to be useful for the treatment of Escherichia coli infection.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12C) mutant inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested cyclopenta-thieno-diazepine derivatives acting as GABA-A receptor subunit α2β2γ1 positive allosteric modulators (PAMs). As such, they are reported to be useful for the treatment of neurological disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be useful for the treatment of subacute sclerosing panencephalitis, progressive supranuclear palsy, frontotemporal dementia and Alzheimer's disease, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged imidazole derivatives reported to be useful for the treatment of bacterial infections.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
